Pacira Pharma (PCRX) Tops Q4 EPS by 12c, Revenue Beats; Offers FY20 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Pacira Reports Record Fourth Quarter and Full-Year Revenues
February 20, 2020 8:01 AM EST Full-year 2019 revenue increases 25 percent to $421 million versus 2018
Total 2020 revenue guidance of between $485 million and $500 million
Anesthesia-driven regional approaches are expanding and driving strong EXPAREL growth
Conference call today at 8:30 a.m. ET
PARSIPPANY, N.J., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today reported financial results for the fourth quarter and full-year of 2019 and provided 2020 financial guidance.
By every measure, 2019 was an outstanding year for Pacira. We are delighted to report record revenues for EXPAREL® with our sixth consecutive quarter of more than 20... More
Pacira Reports Record Fourth Quarter and Full-Year Revenues
February 20, 2020 8:00 AM ESTFull-year 2019 revenue increases 25 percent to $421 million versus 2018 Total 2020 revenue guidance of between $485 million and $500 million Anesthesia-driven regional approaches are expanding and driving strong EXPAREL growth Conference call today at 8:30 a.m. ET
PARSIPPANY, N.J., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today reported financial results for the fourth quarter and full-year of 2019 and provided 2020 financial guidance.
By every measure, 2019 was an outstanding year for Pacira. We are delighted to report record revenues for EXPAREL® with our sixth consecutive quarter of more than 20 percent growth, said Dave... More
